Uncategorized

During this episode of Biotalk, Geoff Meyerson, CEO of Locust Walk, unpacks our 2024 Year-In-Review Report: Global Trends in Biopharma […]

LOCUST WALK NEWS Locust Walk Acquisition Corp. Announces Pricing of Upsized $153,000,000 Initial Public Offering PHILADELPHIA and BOSTON, Jan. 7,

Transaction Case Studies MULTI-TRACK ENGAGEMENT LEADING TO AN EQUITY INVESTMENT Situation Assessment Rapid Micro Biosystems is a privately held, commercial

Transaction Case Studies GLOBAL DEAL WITH A JAPANESE COMPANY FOR BRINCIDOFOVIR, A BROAD-SPECTRUM ANTIVIRAL FOR THE TREATMENT AND PREVENTION OF

Transaction Case Studies RAPID M&A ADVISORY Situation Assessment Anokion Bio is Swiss biotechnology company focused on autoimmune diseases by restoring

Transaction Case Studies MULTI-TRACK ENGAGEMENT LEADING TO ACQUISITION OF XYPHOS BY ASTELLAS FOR $120M UPFRONT AND $545M IN MILESTONE PAYMENTS

Transaction Case Studies SELL-SIDE ENGAGEMENT LEADING TO OPTION AGREEMENT FOR GREATER CHINESE RIGHTS TO A RAS PEPTIDE CANCER VACCINE Situation

Transaction Case Studies SELL-SIDE ENGAGEMENT LEADING TO A REVERSE MERGER BETWEEN BIOPHARMX AND TIMBER PHARMACEUTICALS Situation Assessment A wholly-owned subsidiary

Transaction Case Studies MULTI-TRACK ENGAGEMENT LEADING TO $30M EQUITY RAISE Situation Assessment Regenacy was spun-out from Acetylon Pharmaceuticals in connection with Celgene’s acquisition

Transaction Case Studies Chinese Joint Venture to Facilitate Indication Expansion Opportunity Situation Assessment Regenacy was spun-out from Acetylon Pharmaceuticals in